Savara Inc. (SVRA)
NASDAQ$2.775+0.02 (0.72%)
Market Cap
$473.67M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
198 of 924
Rank in Industry
117 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
SVRA Insider Trading Activity
SVRA Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $346,672 | 2 | 40 |
Sells | $290,675 | 3 | 60 |
Related Transactions
| RAMSAY DAVID A | director | 1 | $287,600 | 0 | $0 | $287,600 |
| McCracken Joseph S | director | 1 | $59,072 | 0 | $0 | $59,072 |
| Hawkins Richard J | director | 0 | $0 | 1 | $26,569 | $-26,569 |
| Lowrance David L | Chief Financial Officer | 0 | $0 | 1 | $83,278 | $-83,278 |
| Pauls Matthew | CHIEF EXECUTIVE OFFICER | 0 | $0 | 1 | $180,828 | $-180,828 |
About Savara Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Insider Activity of Savara Inc.
Over the last 12 months, insiders at Savara Inc. have bought $346,672 and sold $290,675 worth of Savara Inc. stock.
On average, over the past 5 years, insiders at Savara Inc. have bought $2.66M and sold $417,956 worth of stock each year.
Highest buying activity among insiders over the last 12 months: RAMSAY DAVID A (director) — $287,600. McCracken Joseph S (director) — $59,072.
The last purchase of 20,000 shares for transaction amount of $59,072 was made by McCracken Joseph S (director) on 2024‑11‑19.
List of Insider Buy and Sell Transactions, Savara Inc.
| 2024-12-16 | Sale | Pauls Matthew | CHIEF EXECUTIVE OFFICER | 54,702 0.0322% | $3.31 | $180,828 | -14.26% | |
| 2024-12-16 | Sale | Lowrance David L | Chief Financial Officer | 25,000 0.0148% | $3.33 | $83,278 | -14.26% | |
| 2024-12-16 | Sale | Hawkins Richard J | director | 8,000 0.0047% | $3.32 | $26,569 | -14.26% | |
| 2024-11-19 | McCracken Joseph S | director | 20,000 0.0117% | $2.95 | $59,072 | -2.89% | ||
| 2024-11-18 | RAMSAY DAVID A | director | 100,000 0.0566% | $2.88 | $287,600 | -3.38% | ||
| 2023-12-28 | Sale | Pauls Matthew | CHIEF EXECUTIVE OFFICER | 84,000 0.0609% | $4.71 | $395,900 | -9.75% | |
| 2023-12-28 | Sale | Lowrance David L | CHIEF FINANCIAL OFFICER | 10,000 0.0072% | $4.71 | $47,131 | -9.75% | |
| 2023-12-28 | Sale | Elam Nevan C | director | 93,843 0.068% | $4.71 | $442,291 | -9.75% | |
| 2023-07-17 | Yang Rick | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.80% | ||
| 2023-07-17 | Walker Paul Edward | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.80% | ||
| 2023-07-17 | SANDELL SCOTT D | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.80% | ||
| 2023-07-17 | Mathers Edward T | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.80% | ||
| 2023-07-17 | Makhzoumi Mohamad | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.80% | ||
| 2023-07-17 | Growth Equity Opportunities 17, LLC | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.80% | ||
| 2023-07-17 | Florence Anthony A. Jr. | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.80% | ||
| 2023-07-17 | Chang Carmen | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.80% | ||
| 2023-07-17 | Behbahani Ali | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.80% | ||
| 2023-07-17 | BASKETT FOREST | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.80% | ||
| 2023-06-26 | Pratt Raymond Dennis | Chief Medical Officer | 6,500 0.0047% | $2.93 | $19,045 | +52.64% | ||
| 2023-05-26 | RAMSAY DAVID A | director | 37,124 0.024% | $2.63 | $97,599 | +44.36% |
Total: 150
*Gray background shows transactions not older than one year
Insider Historical Profitability
38.4%
| RAMSAY DAVID A | director | 2323642 1.354% | $6.41M | 52 | 0 | +46.58% |
| Pauls Matthew | CHIEF EXECUTIVE OFFICER | 1536379 0.8952% | $4.24M | 10 | 2 | <0.0001% |
| Lowrance David L | Chief Financial Officer | 381005 0.222% | $1.05M | 3 | 12 | +23.24% |
| McCracken Joseph S | director | 210837 0.1229% | $581,910.12 | 3 | 0 | +29.35% |
| SANDELL SCOTT D | 10 percent owner | 24471264 14.2591% | $67.54M | 1 | 0 | +32.8% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$587,109,125 | 90 | 3.17% | $509.59M | |
Savara Inc. (SVRA) | $14,527,743 | 76 | 38.40% | $473.67M |
$678,065,999 | 37 | -13.32% | $562.11M | |
$26,923,982 | 20 | -17.22% | $415.61M | |
$6,280,187 | 19 | 6.80% | $482.63M |
SVRA Institutional Investors: Active Positions
| Increased Positions | 84 | +67.2% | 24M | +14.83% |
| Decreased Positions | 51 | -40.8% | 21M | -12.99% |
| New Positions | 32 | New | 9M | New |
| Sold Out Positions | 19 | Sold Out | 11M | Sold Out |
| Total Postitions | 158 | +26.4% | 164M | +1.84% |
SVRA Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Nea Management Company, Llc | $60,933.00 | 14.23% | 24.47M | 0 | 0% | 2024-12-31 |
| Bain Capital Life Sciences Investors, Llc | $36,268.00 | 8.47% | 14.57M | 0 | 0% | 2024-12-31 |
| Tcg Crossover Management, Llc | $30,782.00 | 7.19% | 12.36M | 0 | 0% | 2024-12-31 |
| Vestal Point Capital, Lp | $26,830.00 | 6.27% | 10.78M | +3M | +33.19% | 2024-12-31 |
| Blackrock, Inc. | $23,874.00 | 5.57% | 9.59M | +189,012 | +2.01% | 2024-12-31 |
| Frazier Life Sciences Management, L.P. | $21,564.00 | 5.04% | 8.66M | +502,994 | +6.17% | 2024-12-31 |
| Vanguard Group Inc | $20,692.00 | 4.83% | 8.31M | +365,959 | +4.61% | 2024-12-31 |
| Deerfield Management Company, L.P. (Series C) | $19,830.00 | 4.63% | 7.96M | +1M | +23.17% | 2024-12-31 |
| Nantahala Capital Management, Llc | $18,738.00 | 4.38% | 7.53M | +2M | +45.25% | 2024-12-31 |
| Farallon Capital Management Llc | $17,019.00 | 3.97% | 6.83M | +2M | +49.89% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.